Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

153
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
153
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

328
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
328
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

190
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
190
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

354
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
354
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

229
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
229
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

969
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
969

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A tumor-targeted heptamethine cyanine dye suppresses triple-negative breast cancer by induction of lethal autophagy.

Theranostics·2026
Same author

Potential Effects of Prepubertal Exposure to Perfluorooctane Sulfonic Acid on the First Wave of Folliculogenesis in Young CD-1 Mice.

Birth defects research·2026
Same author

Targeting the Apelin-APJ Axis: A Promising Strategy to Mitigate Anthracycline-Induced Cardiotoxicity.

Cardiovascular toxicology·2026
Same author

Exploratory comparative pharmacokinetic study of a fixed-dose combination of telmisartan/amlodipine/chlorthalidone: half-dose (20/2.5/6.25 mg) versus conventional dose (40/5/12.5 mg).

Translational and clinical pharmacology·2026
Same author

Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study.

Cardiovascular toxicology·2026
Same author

Assessment of Pharmacokinetics and Food Effect of AD-109, a Novel Formulation of Rivaroxaban 18 mg.

Clinical and translational science·2025

Related Experiment Video

Updated: Jan 6, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.2K

Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study.

Taewon Lee1, David Douglass2, Kimo Stine2

  • 1Division of Applied Mathematical Sciences, College of Science and Technology, Korea University, Sejong, Republic of Korea.

Cardiovascular Toxicology
|October 17, 2025
PubMed
Summary
This summary is machine-generated.

This study developed a predictive model to assess the risk of heart damage in children undergoing anthracycline chemotherapy. The model identifies key factors to help predict cardiotoxicity early in pediatric cancer patients.

Keywords:
AnthracyclinesLogistic regressionMyocardial injuryPediatric cancerRisk prediction model

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.7K

Related Experiment Videos

Last Updated: Jan 6, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.2K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.7K

Area of Science:

  • Cardiology
  • Pediatric Oncology
  • Computational Biology

Background:

  • Anthracycline chemotherapy is vital for treating childhood cancers but can cause long-term cardiotoxicity.
  • Early detection of anthracycline-induced cardiotoxicity in pediatric patients is limited due to a lack of predictive tools.
  • Existing risk models primarily focus on hematological toxicity, not cardiac complications.

Purpose of the Study:

  • To develop and validate a pilot risk prediction model for anthracycline-induced cardiotoxicity in children.
  • To identify key clinical and treatment variables associated with myocardial injury in pediatric cancer patients.
  • To improve early risk stratification for cardiotoxicity in this vulnerable population.

Main Methods:

  • A pilot study analyzed data from 18 children receiving anthracycline-based chemotherapy.
  • Paired-sample design with patient demographics, clinical features, and treatment regimens as input variables.
  • High-sensitivity cardiac troponin T plasma concentration was the outcome measure for myocardial injury; logistic regression and Leave-One-Patient-Out Cross-Validation were employed.

Main Results:

  • A preliminary model was developed using 13 key variables, refined from an initial 33.
  • Four significant predictors of myocardial injury were identified: sex, age at diagnosis, total cyclophosphamide dose, and days since the first anthracycline dose.
  • The final logistic regression model demonstrated high predictive performance: 85% accuracy, 80% sensitivity, 88% specificity, AUC of 0.89, and Youden's index of 0.68.

Conclusions:

  • The developed predictive model shows promise for stratifying the risk of anthracycline-induced myocardial injury in pediatric cancer patients.
  • This tool could aid in early identification and management of cardiotoxicity, improving long-term outcomes for childhood cancer survivors.
  • Further validation in larger cohorts is warranted to confirm the model's clinical utility.